The cardiac effects of mitoxantrone: Do the benefits in multiple sclerosis outweigh the risks?

Expert Opinion on Drug Safety

Volumn 5, Issue 2, 2006, Pages 265-274

  Murray, T Jock ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Cardiotoxicity; Leukaemia; Mitoxantrone; Multiple sclerosis (MS); Novantrone ; Relapsing remitting multiple sclerosis (RRMS); Secondary progressive multiple sclerosis (SPMS); Worsening multiple sclerosis

Indexed keywords

ANTHRACYCLINE; AZATHIOPRINE; CYCLOPHOSPHAMIDE; GAMMA GLUTAMYLTRANSFERASE; GLATIRAMER; INTERFERON; INTERFERON BETA SERINE; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; PLACEBO; RAZOXANE; IMMUNOSUPPRESSIVE AGENT;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; AMENORRHEA; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; BREAST CANCER; CARDIOTOXICITY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DISEASE COURSE; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG FATALITY; DRUG INDUCED CANCER; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HAIR LOSS; HEART ARRHYTHMIA; HEART DEATH; HEART DISEASE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART PROTECTION; HUMAN; LEUKEMIA; LEUKOPENIA; LOW DRUG DOSE; MALIGNANT NEOPLASTIC DISEASE; MENINGITIS; MENSTRUATION DISORDER; MULTIPLE SCLEROSIS; NAUSEA; NEUTROPENIA; NONHUMAN; PLASMAPHERESIS; PRACTICE GUIDELINE; REVIEW; RISK BENEFIT ANALYSIS; SCLERA DISEASE; SEPTIC SHOCK; STEM CELL TRANSPLANTATION; TACHYCARDIA; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; HEART; HEART LEFT VENTRICLE FUNCTION;

DISEASE PROGRESSION; HEART; HEART DISEASES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKEMIA; MITOXANTRONE; MULTIPLE SCLEROSIS; VENTRICULAR FUNCTION, LEFT;

EID: 33644903476     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.5.2.265     Document Type: Review

References (42)

1. GOODIN DS, FROHMAN EM, GARMANY GP et al.: Disease modifying therapies in multiple sclerosis: report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology and the MS council for clinical practice guidelines. Neurology (2002) 58:169-178.
2. WEINER HL, MACKIN GA, ORAV EJ et al.: Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group. Neurology (1993) 43:910-918.
3. CANADIAN COOPERATIVE MS STUDY GROUP: The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. Lancet (1991) 337:441-446.
4. HARTUNG HP, CONSETTE R, KÕNIG N et al.: Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind randomized, multicenter trial. Lancet (2002) 360:2018-2025.
5. CONSETTE RE, DEMONTY L: Immunosupression with mitoxantrone in multiple sclerosis: a pilot study for 2 years in 22 patients. Neurology (1990) 40:261 (Abstract).
6. GOODIN DS, ARNASON BG, COYLE PK, FROHMAN EM, PATY DW: The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology (2003) 61:1332-1338.
7. BASTIANELLO S, POZILLI C, D'ANDREA F et al.: A controlled trial of mitoxantrone in multiple sclerosis.: serial MRI evaluation at one year. Can. J. Neurol. Sci. (1994) 21:266-270.
8. MAUCH E, EISENMANN S, HAHN A et al.: Mitoxantrone (MITOX) in the treatment of multiple sclerosis (MS): a large single center experience. Proceedings of the 124th Annual Meeting of the American Neurological Association, Seattle, USA (1999) (Abstract).
9. ETEMADIFAR M, HAMZEHLOO A: Mitoxantrone reduced disability in Iranian patients with multiple sclerosis. Multiple Sclerosis. (Poster abstract 0497A) Presented at The World Congress of Neurology, Sydney, Australia (2005).
10. LEPAGE E, LERAY E, COUSTANS M, CHAPERON J, EDAN G: Clinical impact of mitoxantrone in 100 consecutive aggressive realapsing-remitting multiple sclerosis patients: a 5 year follow-up observational study. Mult. Scler. (2005) 11(Suppl. 1):S171. (Abstract).
11. TÉLLEZ N, RÍO J, TINTORI M, ROVIRA Á, NOS C, GALÁN Í et al.: Mitoxabtrone in MS patients, non-responders to interferon. Mult. Scler. (2005) 11(Suppl. 1):S172 (Abstract).
12. FOX E, AL-SABBAGH A, BENNETT R, SADIQ S: Safety and tolerability of Novantrone® (mitoxantrone) in clinical practice: Status report from the Registry to evaluate Novantrone® effects in worsening MS (RENEW) study. Neurology (2005) 64(Suppl. 1):A394 (Abstract).
13. EDAN G, BROCHET B, CLANET M et al.: Safety profile of mitoxantrone in a cohort of 800 multiple sclerosis patients. Mult. Scler. (2001) 7(Suppl. 1):S14 (Abstract).
14. JEFFERY DR: Use of combination therapy with immunomodulators and immunosuppressants in treating multiple sclerosis. Neurology (2004) 63(Suppl. 6):S41-S46 (Abstract).
15. NO AUTHORS LISTED: NOVANTRONE (mitoxantrone) package insert, Immunex Corporation, Seattle (2002).
16. GONSETTE RE: Mitoxantrone in progressive multiple sclerosis: when and how to treat? J. Neurol. Sci. (2003) 206:203-208.
17. SYED AR, ZWIBEL H, FOX EJ: Mitoxantrone for multiple sclerosis in clinical practice. Neurology (2004) 63(Suppl. 6):S25-S27.
18. GHALIE RG, EDAN G, LAURENT M, MAUCH E et al.: Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS. Neurology (2002) 59:909-913.
19. POSNER LE, DUKARTG, GOLDBERG J et al.: Mitoxantrone: an overview of safety and toxicity. Invest. New Drugs (1985) 3:123-132.
20. BENJAMIN RS, CHAWLA SP, EWER MS et al.: Evaluation of mitoxantrone cardiac toxicity by nuclear angiography and endomyocardial biopsy: an update. Invest. New Drugs (1985) 3:117-121.
21. BRASSAT D, RECHER C, WAUBANT E et al.: Therapy-related acute myeloblastic leukemia after mitoxantrone treatment in a patient with MS. Neurology (2002) 59:954-955.
22. VOLTZ R, STARCK M, ZINGLER V, STRUPP M, KOLB H-J: Mitoxantrone therapy in multiple sclerosis and acute leukemia: a case report out of 644 treated patients. Mult. Scler. (2004) 10(4):472-474.
23. FELIX CA: Secondary leukemias induced by topoisomerase-targeted drugs. Biochem. Biophys. Acta (1998) 140:233-255.
24. LEVINE S, SALTZMAN A: Regional suppression, therapy after onset and prevention of relapses in experimental allergic encephalomyelitis by mitoxantrone. J. Neuroimmunol. (1986) 13:175-181.
25. NOSEWORTHY J, HOPKINS MB, VANDERVOORT MK et al.: An open trial evaluation of mitoxantrone in the treatment of progressive MS. Neurology (1993) 43:1401-1406.
26. MILLEFIORINI E, GASPERINI C, POZZILLI C et al.: Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. J. Neurol. (1997) 244:153-159
27. HARTUNG HP, GONSETTE R, MORRISSEY S, KRAPF H, FAZEKAS F: Mitoxantrone. In: Rudick RA, Goodkin DE (Eds.), Multiple Sclerosis Therapeutics, London Martin Dunitz, (1999):335-348.
28. KRAPF H, MORRISSEY SP, ZENKER O, ZWINGERS T, GONSETTE R, HARTUNG HP, AND THE MIMS STUDY GROUP: Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial. Neurology (2005) 65:690-695.
29. FOX E, RENEW STUDY TEAM: Evaluation of safety and tolerability of mitoxantrone in the continuation of the worsening multiple sclerosis (RENEW) study. Proceeding of the Consortium of MS Centers, Orlando, USA (2005):77.
30. JEFFERY DR, CHEPURI N, DURDEN D, BURDETTE J: A pilot trial of combination therapy with mitoxantrone and interferon beta-1b using monthly gadolinium-enhanced magnetic resonance imaging. Mult. Scler. (2005) 11(3):296-301.
31. AVASARALA JR, CROSS AH, CLIFFORD DB et al.: Rapid onset mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis. Mult. Scler. (2003) 9:59-62
32. ETEMADIFAR M, HAMZEHLOO A: Secondary Amenorrhea associated with mitoxantrone therapy in patients with multiple sclerosis. Presented at The World Congress of neurology, Sydney, Australia (2005) Poster abstract 0497B.
33. MACLEAN H, FREEDMAN MS, ATKINS HL et al.: Mitoxantrone therapy in multiple sclerosis Mult. Scler. (2005) 11(Suppl. 1):S171 (Abstract).
34. KALLWEIT U, RAJDA E, POEHLAU D: Mitoxantrone treatment of secondary progressive multiple sclerosis patients with EDSS > 6. Mult. Scler. (2005) 11(Suppl. 1):S172 (Abstract).
35. VOLLMER T, CAMPAGNOLO: Symptom control and quality of life following mitoxantrone treatment. Proceedings of Consortium of MS Centers Meeting, Orlando, USA (2005):61.
36. VOLLMER T, PANITCH H, DUNN S, LUBLIN FD, O'CONNOR PW, BAR-OR A et al.: Induction treatment with mitoxantrone (Novantrone®) preceeding treatment with glatiramer acetate (Copaxone®), a multi-center randomized two-arm, open-label study in RRMS patients. Mult. Scler. (2005) 11(Suppl. 1):S87 (Abstract).
37. KITA M, CHOW E, DAVID R: A pilot study of mitoxantrone plus dexrazoxane versus mitoxantrone in patients with relapsing remitting, secondary progressive and progressive relapsing MS. Neurology (2005) 64(Suppl 1)A330 (Abstract).
38. COHEN BA, JEFFERY DR: Identification of suboptimal responders to immune modulating agents and the role of mitoxantrone in worsening multiple sclerosis. Neurology (2004) 63(12) (Suppl. 6):S1-S2.
39. SCOTT LJ, FIGGITT DP: Mitoxantrone: a review of its use in multiple sclerosis. CNS Drugs (2004)18:379-396.
40. MAO-DRAAYER Y, FILLIPI CG, PANITCH HS. Mitoxantrone treatment effect on lupoid sclerosis is independent of autoantibody levels. Presented at The World Congress of Neurology, Sydney, Australia (2005). Poster abstract 0535.
41. COHEN BA, MIKOL DD: Mitoxantrone treatment of multiple sclerosis: safety considerations. Neurology (2004) 63(Suppl. 6):S28-S32.
42. CAON C, DIN M, MADAK S, TSELIS A, LISAK R, KHAN O: Two year open-label observational study comparing monthly intravenous (IV) cyclophosphamide (CTX) and every three month IV mitoxantrone (MIT) in worsening MS patients. Neurology (2005) 64(Suppl. 1):A329 (Abstract).